ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Abstract Number: 2027

Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
Abstract Number: 0090

Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis
Abstract Number: 0562

Large-Scale Targeted Sequencing Study Links Systemic Juvenile Idiopathic Arthritis with Rare Variants of MEFV, LYST, STXBP2, UNC13D
Abstract Number: 1402

Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry
Abstract Number: 1482

Latent Tuberculosis Infection and Its Associations with Clinical and Serological Parameters in Systemic Lupus Erythematosus
Abstract Number: 1456

Latin-American Systemic Lupus Erythematosus Clusters
Abstract Number: 0202

Learning Needs Assessment for Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
Abstract Number: PP08

Learning to Advocate for Myself and the Young Adult Community While Finding My Place as a Patient Partner at CARRA (Childhood Arthritis and Rheumatology Research Alliance)
Abstract Number: 1862

Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
Abstract Number: 1860

Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis
Abstract Number: 0161

Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells
Abstract Number: 1281

Less Than Half of Cryoglobulin Tests Ordered at a Tertiary Hospital Network Are Successfully Completed: An Opportunity for Improvement
Abstract Number: 0824

Lessons Learned from a Cohort of Adult Afro-Caribbean Patients Diagnosed Clinically with Dermatomyositis
Abstract Number: 1698

LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses
Abstract Number: 0226

Linguistics Biases in Letters of Recommendation Written for Rheumatology Fellowship Applicants
Abstract Number: 2163

Lipid Profile in Scleroderma Patients and the Associations of Its Changes with Disease-specific Features
Abstract Number: 1963

Lipid Screening and Statin Use in Rheumatoid Arthritis Patients in an Underserved Population
Abstract Number: 0254

Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial
Abstract Number: PP19

Living with Rheumatoid Arthritis in a Rural Farming Community: How I Found a Rheumatologist and Got Targeted Treatment
Abstract Number: 1559

Long Term Clinical Effects of Apremilast on Behcet’s Disease and Changes in Serum Cytokines
Abstract Number: 0890

Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Disease Activity, MRI Inflammation and Physical Function in Rheumatoid Arthritis Patients in Clinical Remission: Five Year Follow-up of the IMAGINE-RA Cohort
Abstract Number: 2056

Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
Abstract Number: 0644

Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon
Abstract Number: 1578

Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
Abstract Number: 0408

Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Abstract Number: 0806

Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression
Abstract Number: 2212

Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis – an Extension Study of 2 Phase 1b Clinical Trials
Abstract Number: 0272

Long-Term Efficacy of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Bdmards: Results from RA-BEYOND up to 6.9-Years of Treatment
Abstract Number: 2111

Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Abstract Number: 0470

Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial
Abstract Number: 1521

Long-term Follow-Up of Participants of the Phase II Study That Evaluated Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis (ASSET Trial)
Abstract Number: 0431

Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept
Abstract Number: 2009

Long-term Outcome of a Treat-to-target Strategy in Elderly-onset Rheumatoid Arthritis with Chronic Lung Diseases
Abstract Number: 2191

Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea
Abstract Number: 2121

Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
Abstract Number: 1636

Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort
Abstract Number: 1652

Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter, Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study
Abstract Number: 0309

Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study
Abstract Number: 0358

Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis
Abstract Number: 1042

Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis
Abstract Number: 0293

Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND
Abstract Number: 1423

Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting
Abstract Number: 0355

Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
Abstract Number: 0018

Longitudinal Development of Cartilage Microbial DNA Profiles Following Oral Microbiome Inoculation
Abstract Number: 1407

Longitudinal Lipid Profile and NT-proBNP Changes from Pre-clinical to Established Rheumatoid Arthritis: A 12 Years Follow up Explorative Study
Abstract Number: 1088

Longitudinal Pattern of Circulating Complement Activation in ANCA Vasculitis
Abstract Number: 0492

Longitudinal Tends of Hospitalizations for Giant Cell Arteritis: A 21-year Longitudinal National Population-based Study
Abstract Number: 0505

Longitudinal Trajectories of Central Pain Sensitization in People with or at Risk of Knee Osteoarthritis
Abstract Number: 0360

Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Abstract Number: 1869

Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity
Abstract Number: 0554

Loss of Synovial Tissue Macrophage Homeostasis Precedes Rheumatoid Arthritis Clinical Onset
Abstract Number: 0782

Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab
Abstract Number: 1027

Low Dose Computed Tomography Hounsfield Units: A Reliable Methodology for Assessing Changes in Vertebral Bone Density in Radiographic Axial Spondyloarthritis
Abstract Number: 0693

Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)
Abstract Number: 0165

Low Paraoxonase-1 Enzyme Activity in Patients with Idiopathic Inflammatory Myopathies Associates with Cancer Diagnosis
Abstract Number: 0976

Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
Abstract Number: 1318

Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on Bone Mineral Density: Baseline Findings in a Cohort of Rheumatic Disease Patients with Prior Glucocorticoid Exposure
Abstract Number: 0060

Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission
Abstract Number: 0270

Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis
Abstract Number: 2010

Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy
Abstract Number: 1393

Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA Prospective Study
Abstract Number: 1569

Lung Involvement in VEXAS Syndrome
Abstract Number: 1062

Lung Magnetic Resonance Imaging in Systemic Sclerosis Associated Interstitial Lung Disease: Potentiality and Comparison with Other Imaging Techniques
Abstract Number: 1247

Lung Ultrasound in Patients with Connective Tissue Disease-associated Interstitial Lung Disease; Utility of Single Evaluation in Clinical Practice
Abstract Number: 2222

Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile
Abstract Number: 0645

Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions
Abstract Number: 0183

LupusConnect™: A 24/7 Online Lupus Support Community
Abstract Number: 1443

Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features
Abstract Number: 1439

Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections
Abstract Number: 0654

Lymphatic Dysfunction and Immune Activation in Lupus
Abstract Number: 0830

Lymphopenia as a Marker of Disease Activity and Severity in Sarcoidosis

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.